Hemotune raises €7.1M Series B round

26 April 2022· Zurich, Switzerland· health, medtech, nanotechnology, biotech, magnetic_separation, b2b, software_hardware

The Series B1 funding will allow hemotune to complete the preclinical development of its HemoSystem and prepare for a clinical trial in its lead indication, sepsis-associated immunosuppression.

Investors

LeadOCCIDENT

Also participating

Zürcher KantonalbankVP Venture PartnersHEMEXglobal family officeprivate individuals

About Hemotune

Stage

Series B

Headquarters

Zurich, Switzerland

Founded

2017

Team Size

21–50

Sectors

healthmedtechnanotechnologybiotechmagnetic_separationb2bsoftware_hardware

https://www.hemotune.ch

Source: https://www.venturekick.ch/hemotune-raises-CHF-725-million-Series-B1-funding-for-the-development-of-their-disruptive-blood-purification-platform, https://swissbiotech.org/hemotune-raises-chf-7-25-million-to-develop-blood-purification-platform/, https://hemex.ch/news/hemotune-raises-chf-7-25-million-series-b1-funding-for-the-development-of-their-disruptive-blood-purification-platform/